Efficacy and Safety of Intra-vitreal Bevacizumab (Avastin®) Using Pro Re Nata Regimen in Treatment of Macular Edema Due to Retinal Vein Occlusion
Pınar SULTAN1, Sema Çökem ARVAS|2, Ahmet Murat SARICI3, Didar UÇAR4, Funda DİKKAYA5
1M.D. Istanbul Training and Research Hospital, Eye Clinic, Istanbul/TURKEY 2M.D. Professor, Istanbul University, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul/TURKEY 3M.D. Associate Professor, Istanbul University, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul/TURKEY 4M.D., Istanbul University, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul/TURKEY 5M.D. Istanbul Medipol University, Department of Ophthalmology, Istanbul/TURKEY
Purpose: The objectives were to evaluate visual acuity, macular thickness and side effects after intravitreal bevacizumab (IVB) administered
Pro Re Nata (PRN) for macular edema due to branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO)
Materials and Methods: We retrospectively studied the patients with macular edema secondary to BRVO and CRVO, who were treated with
IVB. Best corrected visual acuity (BCVA), central macular thickness and intraocular pressure (IOP) measurements before, 1 month, 4 month,
6 month, 12 month, 24 month and the last injection were recorded. Also risk factors and complications were recorded.
Results: Forty-five eyes of 45 patients (26 BRVO, 19 CRVO) were included. The mean age was 59.24±12.26 years (range, 34-82 years) and
mean follow-up time was 24.36±29.09 months ( range, 4-120 months). The average injection number was determined to be 4.62±2.89 (3-16).
Hypertension was the most common systemic disease (59.9%) and glaucoma was the most common eye disease (11.1%). In BRVO group after
IVB both BCVA and mean central foveal thickness significantly improved (p<0.05) at each follow-up but in CRVO group, there was no statistically
significant improvement of BCVA and mean central foveal thickness (p>0.05). Both BRVO and CRVO group, there was no statistically
significant change of IOP (p>0.05).
Conclusion: The results indicate that specialized systemic and ocular diagnostic examinations are necessary in light of the potential risk factors.
For macular edema secondary to BRVO and CRVO, IVB administered PRN seem to be more effective in BRVO patients than CRVO.